Lupus Market Overview
Over the forecast period, the Lupus Market is predicted to increase rapidly. The lupus market is expected to reach USD 1791.73 million in 2020 and increase at a CAGR of 12.70 percent between 2022 and 2030. Lupus is an autoimmune disease that causes extensive inflammation throughout the body. In lupus sufferers, the immune system attacks healthy cells and tissues, causing damage to the skin, joints, kidneys, heart, lungs, blood vessels, and brain, among other bodily parts.
Factors such as rising lupus prevalence, continuous medical developments in the treatment of systemic lupus erythematosus, and increased research and development efforts are projected to propel the lupus market forward throughout the forecast period. Despite the drivers, market expansion may be hampered by obstacles such as rigorous government regulation and rising lupus medication prices throughout the assessment period. There are a lot of businesses in the lupus market presently.
The Lupus Market has been segmented into types, treatment, and end user. The global market, on the basis of type, has been segmented into systemic lupus erythematosus, cutaneous lupus erythematosus, drug-induced lupus erythematosus, and neonatal lupus. The systemic lupus erythematosus segment is expected to hold the largest market share owing to the growing prevalence and increasing drug development in recent years.
On the basis of treatment, the market has been segmented into nonsteroidal anti-inflammatory drugs (NSAIDs), antimalarial drugs, corticosteroids, immunosuppressants, biologics, and other.
On the basis of end user, the market has been segmented into hospital & clinics, diagnostic laboratories, and others.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The lupus market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European lupus market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The lupus market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The lupus market in the Middle East & Africa has been segmented into the Middle East and Africa.
Aurinia Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Cadila Healthcare, GlaxoSmithKline plc, Mylan N.V., F. Hoffmann-La Roche AG, Pfizer, Inc., Sanofi, Lycera Corporation, Merck KGaA, and Eli Lily and Company are some of the key players in the global lupus market.
Regional Market Summary
Global Lupus Market Share (%), by Region, 2017
Source: White Papers, Company Presentations, Annual Reports
Geographically, the Americas is anticipated to dominate the lupus market owing to the rising demand for better treatment options, growing prevalence of lupus, government initiatives for lupus, and availability of reimbursement. Additionally, the developed healthcare infrastructure and accessibility to biologics are expected to contribute to the market growth in the region.
Europe is expected to hold the second largest position in the lupus market. The market growth in this region is attributed to the rising number of research and development activities and the increasing prevalence of lupus in the region.
The lupus market in the Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be the fastest growing region owing to the growing prevalence of lupus, continuously growing healthcare sector and increasing regional expansion by prominent market players. According to the Australian Society of Clinical Immunology and Allergy, in 2016, it was estimated that lupus affected more than 20,000 people in Australia and New Zealand.
The Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.
Roche is a biotechnology business that produces medications and diagnostics for the treatment of various illnesses. It sells drugs to treat cancer, autoimmunity, central nervous system illnesses, and diabetes management treatments are also available from the firm. Roche undertakes research to discover new approaches to illness prevention, diagnosis, and treatment. Hospitals, commercial laboratories, healthcare professionals, researchers, and pharmacists are among the customers of the company's goods and services. The corporation has activities in a number of countries throughout the world, thanks to its subsidiaries and partners. The headquarters of Roche is in Basel, Switzerland.
Lycera Corporation is a biopharmaceutical product discovery and development company. Rheumatoid arthritis, multiple sclerosis, psoriasis, and inflammatory bowel disease are among the autoimmune disorders for which the company develops innovative oral treatments that are done in a coordinated manner. Lycera's operations are based in the United States.
Lupus Market, by Technique
Lupus Market, by Product
Lupus Market, by End User
Lupus Market, by Region
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Types, Treatment, and End user|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Aurinia Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Cadila Healthcare, GlaxoSmithKline plc, Mylan N.V., F. Hoffmann-La Roche AG, Pfizer, Inc., Sanofi, Lycera Corporation, Merck KGaA, and Eli Lily and Company|
|Key Market Opportunities||New product launches and R&D Amongst major key Players|
|Key Market Drivers||
The lupus market is projected to grow at 12.70% CAGR between 2020-2030.
The Americas is projected to command the largest share in the lupus market.
Growing prevalence of lupus and rising R&D activities are boosting market growth.
High cost of lupus drugs may limit market growth.
Different strategies used by market players to create a dominance in the lupus market include mergers, acquisitions, collaborations, and product developments.